PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-09-20 (1)

Date Title Company
20-Sep-2025 FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) Businesswire